Evidence map›Paper›PMID 36324753›Full record

ReviewFrontiers in cardiovascular medicine2022

Remnant cholesterol and atherosclerotic cardiovascular disease: Metabolism, mechanism, evidence, and treatment.

Kexin Wang, Rui Wang, Jiaxin Yang, Xiaoli Liu, Hua Shen, Yan Sun, Yujie Zhou, Zhe Fang, Hailong Ge

Abstract readReview
In one paragraph

Review in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Association of Remnant Cholesterol With the Retinal Capillary Plexus.Translational vision science & technology · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Relationship between remnant cholesterol inflammatory index and clinical outcome in ischemic stroke patients treated with endovascular thrombectomy.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Observational
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kexin WangDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Rui WangDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Jiaxin YangDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Xiaoli LiuDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Hua ShenDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Yan SunDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Yujie ZhouDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.
Zhe FangJiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, China.
Hailong GeDepartment of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This review aimed to summarize the evidence of elevated remnant cholesterol and the risks of atherosclerotic cardiovascular disease (ASCVD) and to search for further guidance in clinical therapy. The lipids-lowering treatments such as statins and ezetimibe targeted on low-density lipoprotein cholesterol (LDL-C) have always been the first-line therapy for ASCVD. However, even after statins or new lipid-lowering drugs lowered LDL-C to recommended concentrations, and with other risk factors well-controlled, such as high blood pressure, the risks of developing ASCVD remained. Remnant cholesterol (RC) referred to the cholesterol contained in all remnant lipoprotein particles, which was the cholesterol in the hydrolyzed very-low-density lipoprotein and intermediate-density lipoprotein in the fasting state, and the cholesterol in the chylomicron remnants in the postprandial state. Evidence from

Indexed as

atherosclerosiscardiovascular diseasegeneral populationlipoproteinremnant cholesterol

Identifiers

PMID36324753
PMCPMC9621322

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.